Newsletter Signup | Join Community
PCI may improve survival in small cell lung cancer; new study suggests some benefit in early stage NSCLC.
Liquid biopsy improves access to precision cancer medicines and expands NSCLC treatment options.
The precision cancer medicine Tarceva targeting EGFR improves survival in stage I-III NSCLC & appears better than chemo!
Lung Cancer; Risk factors, diagnostic evaluation, staging and treatment planning.
Lung-MAP Precision Medicine Clinical Trial expanded to include all types of NSCLC including squamous and adenocarcinoma.
Stay Current With Lung Cancer Treatment Advances & Connect with Others
Genomic testing for "emerging biomarkers" like HER, MET and RET will become increasingly important for managing NSCLC.
Lung cancer is occurring more frequently in women: understand the causes and what can you do to lower your risk.
The c-Met inhibitor Capmatinib is a promising novel precision cancer medicine for the treatment of EGFR + NSCLC.
The WHO classifies air pollution as a carcinogen & ample evidence is emerging on it overall negative health consequences
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended but…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…